ES2033086T3 - Un procedimiento para la preparacion de una composicion farmaceutica. - Google Patents

Un procedimiento para la preparacion de una composicion farmaceutica.

Info

Publication number
ES2033086T3
ES2033086T3 ES198989300856T ES89300856T ES2033086T3 ES 2033086 T3 ES2033086 T3 ES 2033086T3 ES 198989300856 T ES198989300856 T ES 198989300856T ES 89300856 T ES89300856 T ES 89300856T ES 2033086 T3 ES2033086 T3 ES 2033086T3
Authority
ES
Spain
Prior art keywords
procedure
preparation
pharmaceutical composition
aqueous
fluids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198989300856T
Other languages
English (en)
Spanish (es)
Inventor
Kozo Cno Sankyo Company Limited Kurihara
Masaru Cno Sankyo Company Limited Murano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP63183127A external-priority patent/JP2632010B2/ja
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Application granted granted Critical
Publication of ES2033086T3 publication Critical patent/ES2033086T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ES198989300856T 1988-01-29 1989-01-27 Un procedimiento para la preparacion de una composicion farmaceutica. Expired - Lifetime ES2033086T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP1912588 1988-01-29
JP11163988 1988-05-10
JP63183127A JP2632010B2 (ja) 1988-01-29 1988-07-22 シクロスポリン製剤

Publications (1)

Publication Number Publication Date
ES2033086T3 true ES2033086T3 (es) 1993-03-01

Family

ID=27282507

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198989300856T Expired - Lifetime ES2033086T3 (es) 1988-01-29 1989-01-27 Un procedimiento para la preparacion de una composicion farmaceutica.

Country Status (8)

Country Link
US (1) US4990337A (OSRAM)
EP (1) EP0327280B1 (OSRAM)
AU (1) AU609242B2 (OSRAM)
CA (1) CA1326995C (OSRAM)
DE (1) DE68900991D1 (OSRAM)
ES (1) ES2033086T3 (OSRAM)
GR (1) GR3004611T3 (OSRAM)
HK (1) HK35697A (OSRAM)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
KR0148748B1 (ko) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
US6007840A (en) * 1988-09-16 1999-12-28 Novartis Ag Pharmaceutical compositions comprising cyclosporins
US7081445B2 (en) * 1989-02-20 2006-07-25 Novartis Ag Cyclosporin galenic forms
US5294604A (en) * 1989-12-20 1994-03-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating ocular diseases by periocular administration of cyclosporine A or G
EP0448091B1 (en) * 1990-03-23 1998-08-05 The Green Cross Corporation Pharmaceutical composition containing slightly water-soluble drug
WO1992020795A1 (en) * 1991-05-17 1992-11-26 Cetus Oncology Corporation INHIBITOR OF NF-λB TRANSCRIPTIONAL ACTIVATOR AND USES THEREOF
US6262022B1 (en) 1992-06-25 2001-07-17 Novartis Ag Pharmaceutical compositions containing cyclosporin as the active agent
DK0642332T3 (da) 1992-05-13 1997-06-16 Sandoz Ltd Ophthalmiske præparater indeholdende cyclosporin
ES2168271T3 (es) 1992-09-25 2002-06-16 Novartis Ag Composiciones farmaceuticas que contienen ciclosporinas.
WO1994008538A1 (fr) * 1992-10-22 1994-04-28 Aktsionernoe Obschestvo 'olvik' Membrane oculaire medicinale et son procede de production
CA2161143A1 (en) † 1993-04-20 1994-10-27 Monika Fleck New pharmaceutical preparations comprising cyclosporin for oral administration
DE4322826A1 (de) * 1993-07-08 1995-01-12 Galenik Labor Freiburg Gmbh Pharmazeutisches Präparat
US20020099067A1 (en) * 1993-07-08 2002-07-25 Ulrich Posanski Pharmaceutical compositions for sparingly soluble therapeutic agents
ATE198041T1 (de) 1993-09-28 2000-12-15 Scherer Gmbh R P Herstellung von weichgelatinekapseln
PH31594A (en) * 1993-09-30 1998-11-03 Janssen Pharmaceutica Nv Oral formulations on an antifungal.
FR2711982B1 (fr) * 1993-11-02 1996-01-19 Saint Gobain Vitrage Canal de transfert et de conditionnement de verre en fusion.
US5952004A (en) * 1994-03-18 1999-09-14 Shire Laboratories Inc. Emulsified drug delivery systems
US5474979A (en) * 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
PT789580E (pt) 1994-11-03 2002-09-30 Novartis Ag Formulacoes de ciclosporina para administracao oral com composicao simples e alta biodisponibilidade e processo para a sua producao
US5824638A (en) * 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
US5766629A (en) * 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US5827822A (en) * 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
US5834017A (en) * 1995-08-25 1998-11-10 Sangstat Medical Corporation Oral cyclopsporin formulations
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
EP0760237A1 (en) * 1995-08-30 1997-03-05 Cipla Limited Oil-in-water microemulsions
DE19544507B4 (de) 1995-11-29 2007-11-15 Novartis Ag Cyclosporin enthaltende Präparate
CZ288631B6 (cs) * 1996-01-18 2001-08-15 Galena, A. S. Léčivé přípravky s obsahem cyklosporinu
US5858401A (en) * 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US5660858A (en) * 1996-04-03 1997-08-26 Research Triangle Pharmaceuticals Cyclosporin emulsions
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US7255877B2 (en) * 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
HU226608B1 (hu) 1996-08-22 2009-04-28 Rtp Pharma Corp Vízoldhatalan anyagok mikrorészecskéit tartalmazó készítmények és ezek elõállítására szolgáló eljárások
KR20040004416A (ko) 1997-01-30 2004-01-13 노파르티스 아게 오일을 함유하지 않은 사이클로스포린 ａ 함유 제약 조성물
DE19724605A1 (de) * 1997-06-11 1998-12-17 Sueddeutsche Kalkstickstoff Hydrophile, homogene Monogycerid-Formulierungen und Verfahren zu deren Herstellung
US6008191A (en) * 1997-09-08 1999-12-28 Panacea Biotec Limited Pharmaceutical compositions containing cyclosporin
US6187747B1 (en) 1997-09-08 2001-02-13 Panacea Biotech Limited Pharmaceutical composition comprising cyclosporin
IN188719B (OSRAM) * 1997-09-08 2002-11-02 Panacea Biotec Ltd
US6346511B1 (en) 1997-09-08 2002-02-12 Panacea Biotec Limited Pharmaceutical composition comprising cyclosporin
CA2313024C (en) 1997-12-10 2008-06-03 Severson, Mary L. Pharmaceutical compositions containing an omega-3 fatty acid oil
DE19810655A1 (de) * 1998-03-12 1999-09-16 Univ Eberhard Karls Arzneimittel mit einem Gehalt an Ciclosporin
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
DE69914742T2 (de) 1998-05-29 2004-11-25 Skyepharma Canada Inc., Verdun Gegen hitzeeinwirkung geschützte mikropartikel und verfahren zur terminalen dampfsterilisation derselben
EP0976394A1 (en) * 1998-07-30 2000-02-02 Biosearch Italia S.p.A. New injectable formulations
RU2233654C2 (ru) 1998-11-20 2004-08-10 Ртп Фарма Инк. Диспергируемые стабилизированные фосфолипидом микрочастицы
CN1236813C (zh) 1998-12-11 2006-01-18 药品处理公司 水难溶性药物的自乳化组合物
US6447806B1 (en) 1999-02-25 2002-09-10 Novartis Ag Pharmaceutical compositions comprised of stabilized peptide particles
US6057289A (en) * 1999-04-30 2000-05-02 Pharmasolutions, Inc. Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system
CN1174741C (zh) * 1999-09-21 2004-11-10 Rtp药品公司 生物活性物质的表面改性微粒组合物
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
WO2001032143A1 (en) * 1999-11-02 2001-05-10 Cipla Ltd. A pharmaceutical composition for the administration of water-insoluble pharmaceutically active substances and a process for preparation thereof
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
GB0008785D0 (en) * 2000-04-10 2000-05-31 Novartis Ag Organic compounds
CA2423336C (en) * 2000-09-20 2011-03-08 Rtp Pharma Inc. Stabilised fibrate microparticles
US8586094B2 (en) * 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
CA2461730C (en) * 2001-10-19 2012-05-15 Isotechnika Inc. Novel cyclosporin analog microemulsion preconcentrates
US6979672B2 (en) 2002-12-20 2005-12-27 Polichem, S.A. Cyclosporin-based pharmaceutical compositions
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US7135455B2 (en) * 2004-11-15 2006-11-14 Allergan, Inc Methods for the therapeutic use of cyclosporine components
US7151085B2 (en) * 2004-11-15 2006-12-19 Allergan, Inc. Therapeutic methods using cyclosporine components
US8673351B2 (en) 2005-03-21 2014-03-18 Ivax Pharmaceuticals S.R.O. Crystallization inhibitor and its use in gelatin capsules
GB2451811A (en) 2007-08-09 2009-02-18 Ems Sa Delivery composition for solubilising water-insoluble pharmaceutical active ingredients
PL2683406T3 (pl) 2011-03-11 2019-11-29 Beth Israel Deaconess Medical Ct Inc Przeciwciała anty-cd40 i ich zastosowania
JP6608917B2 (ja) 2014-09-26 2019-11-20 ザ ケマーズ カンパニー エフシー リミテッド ライアビリティ カンパニー スルホン化フッ素化、非フッ素化、又は部分フッ素化ウレタン
SI3307322T1 (sl) 2015-09-04 2021-08-31 Primatope Therapeutics Inc. Humanizirana protitelesa proti CD40 in njihove uporabe

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE149197C (OSRAM) * 1902-10-24
US2865859A (en) * 1956-11-09 1958-12-23 Irwin I Lubowe Solubilizing of mineral, vegetable, animal oils for cosmetic, pharmaceutical and industrial purposes
US3678149A (en) * 1970-01-26 1972-07-18 Samuel J Prigal Method of enhancing the action of a medicament
SE445174B (sv) * 1978-03-07 1986-06-09 Sandoz Ag Farmaceutisk komposition innehallande en cyklosporin och en berarsubstans
CH641356A5 (en) * 1979-02-27 1984-02-29 Sandoz Ag Pharmaceutical compositions containing cyclosporin
JPS5921613A (ja) * 1982-07-28 1984-02-03 Takeda Chem Ind Ltd 直腸投与製剤
EP0094157B1 (en) * 1982-04-30 1987-07-29 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its use
US4659696A (en) * 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
US4474751A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
BE897724A (fr) * 1983-09-09 1984-01-02 Mallien Denis Systeme de communication selective, bidirectionnelle, par radio, entre un poste de commande et plusieurs postes de travail
DE3339236A1 (de) * 1983-10-28 1985-05-09 Bayer Ag Arzneimittelzubereitung
US4612193A (en) * 1983-12-23 1986-09-16 Del Laboratories, Inc. Sty ointment and method of using the same
US4722914A (en) * 1984-05-30 1988-02-02 Motorola Inc. Method of making a high density IC module assembly
EP0170623B1 (en) * 1984-08-02 1990-11-28 Sandoz Ag Novel pharmaceutical use of (nva)2-cyclosporine
US4649047A (en) * 1985-03-19 1987-03-10 University Of Georgia Research Foundation, Inc. Ophthalmic treatment by topical administration of cyclosporin
US4839342A (en) * 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin

Also Published As

Publication number Publication date
CA1326995C (en) 1994-02-15
GR3004611T3 (OSRAM) 1993-04-28
HK35697A (en) 1997-03-27
US4990337A (en) 1991-02-05
AU609242B2 (en) 1991-04-26
AU2885389A (en) 1989-08-03
EP0327280B1 (en) 1992-03-18
DE68900991D1 (de) 1992-04-23
EP0327280A1 (en) 1989-08-09

Similar Documents

Publication Publication Date Title
ES2033086T3 (es) Un procedimiento para la preparacion de una composicion farmaceutica.
ATE72629T1 (de) Cyclosporin enthaltende pharmazeutische zubereitung.
PT850046E (pt) Microemulsoes para utilizacao como veiculos para administracao de compostos activos
ES2157975T3 (es) Soluciones farmaceuticas con solubilidad mejorada.
SE8504945L (sv) Farmaceutiska kompositioner innehallande antracyklinglykosider
MX9203504A (es) Complejo agente: lipido activo de alta proporcion.
IT1220979B (it) Capsule contenenti un allergene e procedimento per la loro preparazione
AR003933A1 (es) Micelas mixtas, composiciones acuosas que las contienen, procedimiento para la obtencion de las micelas mixtas y empleo de las micelas mixtas.
NO904694L (no) Fremgangsmaate for fremstilling av terapeutisk aktive imidazolderivater.
DE69211691D1 (de) Pharmazeutische formulierung und pharmazeutisches verfahren
NO901684L (no) Fremgangsmaate for fremstilling av terapeutisk aktive 3-substituerte-2-oksindol-derivater.
AR065073A2 (es) Una formulacion medicamentosa de sistema de matriz que tiene liberacion controlada de un compuesto activo
AR224111A1 (es) Derivados de 1-oxido de acido penicilanico,desprovistos de actividad terapeutica,utiles como intermediarios en la preparacion de 1,1-dioxido de acido penicilanico farmaceuticamente activos,procedimiento para preparar dichos intermediarios y procedimiento para preparar los 1,1-dioxidos de acido penicilanico farmaceuticamente activos partiendo de dichos intermediarios
RU93032613A (ru) Фармацевтический препарат для лечения пациентов с пролонгированным временем коагуляции, способ лечения пациентов, применение epi ингибитора для получения фармацевтического препарата
PE38097A1 (es) NUEVA FORMA CRISTALINA DEL ACIDO 7-([1a, 5a, 6a]-6-AMINO-3-AZABICICLO[3.1.0]HEX-3-IL)-6-FLUOR-1-(2,4-DIFLUOROFENIL)-1,4-DIHIDRO-4-OXO-1,8-NAFTIRIDIN-3-CARBOXILICO ANHIDRO, SAL DEL ACIDO METANOSULFONICO
SE8803221L (sv) Vattenloesliga monoestrar som solubiliseringsmedel foer farmakologiskt aktiva foereningar och farmaceutiska excipienter
DK98089A (da) Medikament-lipid-systemer med lav toxicitet
CU22836A3 (es) Sistema de gel de nimesulida para uso tópico
ES459244A1 (es) Un procedimiento para la fabricacion de preparados oftalmi- cos de emision lenta
NO900972L (no) Fremgangsmaate for fremstilling av terapeutisk aktive naftalen-derivater.
AR005724A1 (es) Derivados de ureido biologicamente activos utiles en el tratamiento de esclerosis multiple
ES2057528T3 (es) Pdgf-a, pdgf-aa, pdgf-ab, procedimientos de preparacion y medicamentos que los contienen.
JPS6485990A (en) Antihypertestoeronemia agent
ATE12649T1 (de) Optisch aktives dipeptide, seine pharmazeutisch vertraeglichen salze, verfahren zur herstellung und diese enthaltende pharmazeutische praeparate.
ES2010286A6 (es) Procedimiento para preparar derivados de acidos nucleicos bicatenarios con un tamano molecular entre 4s y 13s

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 327280

Country of ref document: ES